Trial reportEuropean journal of oral sciences2025
Comparative evaluation of the success of Er,Cr:YSGG laser, ferric sulfate, or a herbal hemostatic agent for hemostasis in primary molar pulpotomy.
Trial report in European journal of oral sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of diode laser in pulpotomy: a systematic review and meta-analysis.BMC oral health · 2026Pooled it
- Comparative evaluation of the success of Er,Cr:YSGG laser, ferric sulfate, or a herbal hemostatic agent for hemostasis in primary molar pulpotomy.European journal of oral sciences · 2025Trial
- Beyond hemostasis: a narrative review on the multifaceted therapeutic potential of Ankaferd Blood Stopper.Annals of medicine and surgery (2012) · 2026Review
- Phytotherapy in Pediatric Dentistry: A Narrative Review of Clinical Applications and Evidence.Children (Basel, Switzerland) · 2025Review
- Laser Pulpotomies' Clinical and Radiographic Success in Primary Teeth by Type of Laser.Children (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The objective of this study was to evaluate the clinical and radiographic success of the use of the Er,Cr:YSGG laser, ferric sulfate, or a herbal hemostatic agent for hemostasis in primary molar pulpotomy. Sixty-five children aged 5-9 years with a total of 81 primary mandibular second molars indicated for pulpotomy were included in the study. The teeth were randomly divided into the following three groups according to the pulpotomy agents used: ferric sulfate, herbal hemostatic agent, or Er,Cr:YSGG laser. Following pulpotomy treatments, the patients were followed up for 12 months. Pearson Chi-square and Fisher's exact tests were used for statistical analysis. At the end of the follow-up period, the clinical success rates for ferric sulfate, the herbal hemostatic agent, and the Er,Cr:YSGG laser were 96, 100, and 100%, respectively, while the radiographic success rates were 76, 73, and 96%, respectively. There was a statistically significant difference between treatments with respect to radiographic success rates, with the Er,Cr:YSGG laser showing a higher success rate compared with the other groups. Based on the results of the present study, it can be concluded that the Er,Cr:YSGG laser can be used as a hemostatic agent in the pulpotomy of primary teeth and is considered a suitable alternative to ferric sulfate and the herbal hemostatic agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.